As part of our mission to manage complexity and improve lives, we at Mallinckrodt Pharmaceuticals are committed to supporting research as well as educational programming to accelerate diagnosis and treatment in a variety of therapeutic areas.
The Mallinckrodt 2019
Advancing ECP Immunomodulation Investigator Award:
Call for proposals
After last year’s successful initiation of the “Advancing THERAKOS ECP ImmunomodulationTM Award”
Program, Mallinckrodt, the global leader in extracorporeal photopheresis (ECP), is proud to renew its commitment
with the 2019 edition of this program, part of its mission to continue advancing the science of ECP.
Whether you are a clinician or a scientist involved, or interested, in ECP Immunomodulation, you and your team
may be eligible to apply for this award.
The ECP Investigator Award 2018
In March 2018, Mallinckrodt announced the first honorees of the company’s Advancing Extracorporeal Photopheresis (ECP) Immunomodulation Investigator Award – investigator Dr. Nick Matthews and co-investigator Dr. Arun Alfred of the Department of Haematology at Rotherham NHS Foundation Trust in the United Kingdom.
Investigator Initiated Research
The mission of the Investigator Initiated Research (IIR) Program at Mallinckrodt is to improve the
lives of our patients by increasing the medical and scientific understanding of our products and
related therapeutic areas.
Independent Medical Education Grants
Mallinckrodt is committed to supporting independent, high-quality educational programmes for healthcare professionals that contribute to the improvement of patient care in the therapeutic areas in which the business has research and commercial interests.